The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells
Open accessAbstract
Imiquimod is a synthetic compound with antitumor properties; a 5% cream formulation is successfully used to treat skin tumors. The antitumor effect of imiquimod is multifactorial, although its ability to modulate immune responses by triggering TLR7/8 is thought to be key. Among the immune cells suggested to be involved are plasmacytoid DCs (pDCs). However, a direct contribution of pDCs to tumor killing in vivo and the mechanism of their recruitment to imiquimod-treated sites have never been demonstrated. Using a mouse model of melanoma, we have now demonstrated that pDCs can directly clear tumors without the need for the adaptive immune system. Topical imiquimod treatment led to TLR7-dependent and IFN-α/β receptor 1-dependent (IFNAR1-dependent) upregulation of expression of the chemokine CCL2 in mast cells. This was essential to induce skin inflammation and for the recruitment of pDCs to the skin. The recruited pDCs were CD8α+ and induced tumor regression in a TLR7/MyD88- and IFNAR1-dependent manner. Lack of TLR7 and IFNAR1 or depletion of pDCs or CD8α+ cells from tumor-bearing mice completely abolished the effect of imiquimod. TLR7 was essential for imiquimod-stimulated pDCs to produce IFN-α/β, which led to TRAIL and granzyme B secretion by pDCs via IFNAR1 signaling. Blocking these cytolytic molecules impaired pDC-mediated tumor killing. Our results demonstrate that imiquimod treatment leads to CCL2-dependent recruitment of pDCs and their transformation into a subset of killer DCs able to directly eliminate tumor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement
Shinkai, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90029-c · Cited by 2,150
Targeted Disruption of the MyD88 Gene Results in Loss of IL-1- and IL-18-Mediated Function
Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K., & Akira, S. (1998) · Immunity · doi:10.1016/s1074-7613(00)80596-8 · Cited by 2,041
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3
Kanneganti, T.-D., Özören, N., Body-Malapel, M., Amer, A., Park, J.-H., Franchi, L., Whitfield, J., Barchet, W., Colonna, M., Vandenabeele, P., et al. (2006) · Nature · doi:10.1038/nature04517 · Cited by 1,148
Self-citationLu, B., Rutledge, B. J., Gu, L., Fiorillo, J., Lukacs, N. W., Kunkel, S. L., North, R., Gerard, C., & Rollins, B. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.601 · Cited by 1,017
Zou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1339 · Cited by 653
Regulation of Spontaneous Intestinal Tumorigenesis Through the Adaptor Protein MyD88
Rakoff-Nahoum, S., & Medzhitov, R. (2007) · Science · doi:10.1126/science.1140488 · Cited by 584
Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer
Treilleux, I., Blay, J.-Y., Bendriss-Vermare, N., Ray-Coquard, I., Bachelot, T., Guastalla, J.-P., Bremond, A., Goddard, S., Pin, J.-J., Barthelemy-Dubois, C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0684 · Cited by 460
A novel dendritic cell subset involved in tumor immunosurveillance
Taieb, J., Chaput, N., Ménard, C., Apetoh, L., Ullrich, E., Bonmort, M., Péquignot, M., Casares, N., Terme, M., Flament, C., et al. (2006) · Nature Medicine · doi:10.1038/nm1356 · Cited by 405
Swiecki, M., & Colonna, M. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00881.x · Cited by 397
Self-citationSwiecki, M., Gilfillan, S., Vermi, W., Wang, Y., & Colonna, M. (2010) · Immunity · doi:10.1016/j.immuni.2010.11.020 · Cited by 381
Self-citationPlasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma
Wei, S., Kryczek, I., Zou, L., Daniel, B., Cheng, P., Mottram, P., Curiel, T., Lange, A., & Zou, W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4043 · Cited by 379
Gibson, S. J., Lindh, J. M., Riter, T. R., Gleason, R. M., Rogers, L. M., Fuller, A. E., Oesterich, J. L., Gorden, K. B., Qiu, X., McKane, S. W., et al. (2002) · Cellular Immunology · doi:10.1016/s0008-8749(02)00517-8 · Cited by 375
Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells
Stary, G., Bangert, C., Tauber, M., Strohal, R., Kopp, T., & Stingl, G. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070021 · Cited by 363
Lichtenberger, B. M., Tan, P. K., Niederleithner, H., Ferrara, N., Petzelbauer, P., & Sibilia, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.046 · Cited by 358
Self-citationType I interferon dependence of plasmacytoid dendritic cell activation and migration
Asselin-Paturel, C., Brizard, G., Chemin, K., Boonstra, A., O'Garra, A., Vicari, A., & Trinchieri, G. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041930 · Cited by 343
Liu, C., Lou, Y., Lizée, G., Qin, H., Liu, S., Rabinovich, B., Kim, G. J., Wang, Y.-H., Ye, Y., Sikora, A. G., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33583 · Cited by 316
Molecular mechanism of TNF signaling and beyond
LIU, Z.-G. (2005) · Cell Research · doi:10.1038/sj.cr.7290259 · Cited by 280
Antiviral response by natural killer cells throughTRAIL gene induction by IFN-α/β
Sato, K., Hida, S., Takayanagi, H., Yokochi, T., Kayagaki, N., Takeda, K., Yagita, H., Okumura, K., Tanaka, N., Taniguchi, T., et al. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200111)31:11<3138::aid-immu3138>3.0.co;2-b · Cited by 271
Monleón, I., Martínez-Lorenzo, M. J., Monteagudo, L., Lasierra, P., Taulés, M., Iturralde, M., Piñeiro, A., Larrad, L., Alava, M. A., Naval, J., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.6736 · Cited by 266
Virus or TLR Agonists Induce TRAIL-Mediated Cytotoxic Activity of Plasmacytoid Dendritic Cells
Chaperot, L., Blum, A., Manches, O., Lui, G., Angel, J., Molens, J.-P., & Plumas, J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.248 · Cited by 256
Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells
Penna, G., Vulcano, M., Sozzani, S., & Adorini, L. (2002) · Human Immunology · doi:10.1016/s0198-8859(02)00755-3 · Cited by 252
Mechanisms of Interferon-alpha induced apoptosis in malignant cells
Thyrell, L., Erickson, S., Zhivotovsky, B., Pokrovskaja, K., Sangfelt, O., Castro, J., Einhorn, S., & Grandér, D. (2002) · Oncogene · doi:10.1038/sj.onc.1205179 · Cited by 239
Kohlmeier, J. E., Cookenham, T., Roberts, A. D., Miller, S. C., & Woodland, D. L. (2010) · Immunity · doi:10.1016/j.immuni.2010.06.016 · Cited by 236
The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy
Smits, E. L. J. M., Ponsaerts, P., Berneman, Z. N., & Van Tendeloo, V. F. I. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0097 · Cited by 215
Palamara, F., Meindl, S., Holcmann, M., Lührs, P., Stingl, G., & Sibilia, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3051 · Cited by 201
Self-citationGross, C., Koelch, W., DeMaio, A., Arispe, N., & Multhoff, G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302644200 · Cited by 193
Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion
Jahrsdörfer, B., Vollmer, A., Blackwell, S. E., Maier, J., Sontheimer, K., Beyer, T., Mandel, B., Lunov, O., Tron, K., Nienhaus, G. U., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235382 · Cited by 180
Schön, M. P., Schön, M., & Klotz, K.-N. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700286 · Cited by 164
Stary, G., Klein, I., Kohlhofer, S., Koszik, F., Scherzer, T. M., Müllauer, L., Quendler, H., Kohrgruber, N., & Stingl, G. (2009) · Blood · doi:10.1182/blood-2009-04-217927 · Cited by 138
Schön, M. P., Wienrich, B. G., Drewniok, C., Bong, A. B., Eberle, J., Geilen, C. C., Gollnick, H. P. M., & Schön, M. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22528.x · Cited by 138
The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice
Ma, F., Zhang, J., Zhang, J., & Zhang, C. (2010) · Cellular and Molecular Immunology · doi:10.1038/cmi.2010.30 · Cited by 135
Rajagopal, D., Paturel, C., Morel, Y., Uematsu, S., Akira, S., & Diebold, S. S. (2010) · Blood · doi:10.1182/blood-2009-08-238543 · Cited by 122
Heib, V., Becker, M., Warger, T., Rechtsteiner, G., Tertilt, C., Klein, M., Bopp, T., Taube, C., Schild, H., Schmitt, E., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036889 · Cited by 118
Domains of Interaction between Alpha Interferon and its Receptor Components
Uzé, G., Marco, S. D., Mouchel‐Vielh, E., Monneron, D., Bandu, M., Horisberger, M. A., Dorques, A., Lutfalla, G., & Mogensen, K. E. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1651 · Cited by 117
Immune response modifiers – mode of action
Schiller, M., Metze, D., Luger, T. A., Grabbe, S., & Gunzer, M. (2006) · Experimental Dermatology · doi:10.1111/j.0906-6705.2006.00414.x · Cited by 117
Herzer, K., Hofmann, T. G., Teufel, A., Schimanski, C. C., Moehler, M. H., Kanzler, S., Schulze‐Bergkamen, H., & Galle, P. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2831 · Cited by 96
Sawaki, J., Tsutsui, H., Hayashi, N., Yasuda, K., Akira, S., Tanizawa, T., & Nakanishi, K. (2007) · International Immunology · doi:10.1093/intimm/dxl148 · Cited by 91
Plasmacytoid dendritic cells and cancer
Vermi, W., Soncini, M., Melocchi, L., Sozzani, S., & Facchetti, F. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0411190 · Cited by 91
Imiquimod as an antiangiogenic agent.
Li, V. W., Li, W. W., Talcott, K. E., & Zhai, A. W. (2005) · PubMed · Cited by 85
Papageorgiou, A., Dinney, C. P., & McConkey, D. J. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.6.4088 · Cited by 81
Colisson, R., Barblu, L., Gras, C., Raynaud, F., Hadj-Slimane, R., Pique, C., Hermine, O., Lepelletier, Y., & Herbeuval, J. (2009) · Blood · doi:10.1182/blood-2009-06-224741 · Cited by 76
Ooi, T. C., Barnetson, R. S., Zhuang, L., McKane, S. W., Lee, J. H., Slade, H. B., & Halliday, G. M. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06932.x · Cited by 66
Dexamethasone and FK506 Inhibit Expression of Distinct Subsets of Chemokines in Human Mast Cells
Kato, A., Chustz, R. T., Ogasawara, T., Kulka, M., Saito, H., Schleimer, R. P., & Matsumoto, K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801375 · Cited by 60
Inglefield, J. R., Dumitru, C. D., Alkan, Ş. Ş., Gibson, S. J., Lipson, K. E., Tomai, M. A., Larson, C. J., & Vasilakos, J. P. (2008) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2007.0097 · Cited by 39
Shinbori, T., Walczak, H., & Krammer, P. H. (2004) · European Journal of Immunology · doi:10.1002/eji.200425097 · Cited by 38
Sorrentino, R., Morello, S., Luciano, A., Crother, T. R., Maiolino, P., Bonavita, E., Arra, C., Adcock, I. M., Arditi, M., & Pinto, A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000881 · Cited by 38
Skin Inflammation Is Not Sufficient to Break Tolerance Induced against a Novel Antigen
Holcmann, M., Stoitzner, P., Drobits, B., Lührs, P., Stingl, G., Romani, N., Maurer, D., & Sibilia, M. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0713351 · Cited by 20
Self-citation
Cited by
Dendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
The multifaceted biology of plasmacytoid dendritic cells
Swiecki, M., & Colonna, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3865 · Cited by 1,131
Self-citationMechanisms regulating skin immunity and inflammation
Pasparakis, M., Haase, I., & Nestle, F. O. (2014) · Nature Reviews Immunology · doi:10.1038/nri3646 · Cited by 886
Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J. V., Colgan, J. D., et al. (2012) · Nature Immunology · doi:10.1038/ni.2376 · Cited by 838
Metadata
- Authors
- Drobits, B., Holcmann, M., Amberg, N., Swiecki, M., Grundtner, R., Hammer, M., Colonna, M., & Sibilia, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-02-01
- Volume
- 122
- Issue
- 2
- Pages
- 575-585
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2169988783
- Cited by
- 294
- References
- 51
- FWCI
- 11.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.